ITOS — iTeos Therapeutics Share News
0.000.00%
Last trade - 00:00- $448.68m
- -$66.75m
- $35.00m
U.S. STOCKS ON THE MOVE-Charles Schwab, CACI International, Icahn Enterprises
Iteos falls after mid-stage study results for lung cancer drug
U.S. STOCKS ON THE MOVE-Bausch + Lomb, Alcoa, crypto stocks
U.S. STOCKS ON THE MOVE-Intel, Colgate-Palmolive, Zillow Group
Iteos rises on superior efficacy of lung cancer drug combo vs GSK’s Jemperli alone
Brief: Iteos Announces Clinically Objective Response Rate At Every Dose In Follow-Up Interim Analysis Of Galaxies Lung-201 Study Of Belrestotug + Dostarlimab In First-Line, Pd-L1 High Non-Small Cell Lung Cancer Patients
U.S. RESEARCH ROUNDUP-Airbnb, Dollar General, Walmart
Iteos Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Iteos Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview
Brief: Iteos Announces First Patient Dosed In Galaxies Lung-301 Phase 3 Study, Earning $35 Mln In Milestones From GSK
Brief: Iteos Announces First Patient Dosed In Galaxies Lung-301 Phase 3 Study, Earning $35 Million In Milestones From Gsk
U.S. STOCKS ON THE MOVE-Golar LNG, gold miners, Big Tech
U.S. STOCKS ON THE MOVE-Golar LNG, gold miners, Big Tech
U.S. STOCKS ON THE MOVE-Macy's, Niu, crypto stocks
Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial
Brief: Iteos And GSK Initiate Phase 3 Study Assessing Belrestotug And Dostarlimab In Non-Small Cell Lung Cancer
Iteos Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: iTeos Therapeutics Announces $120 Million Registered Direct Offering
Iteos Therapeutics Inc expected to post a loss of $1.26 a share - Earnings Preview